Oligomeric Aβ in Alzheimer's disease: Relationship to plaque and tangle pathology, apoe genotype and cerebral amyloid angiopathy

Brain Pathology

Volumn 20, Issue 2, 2010, Pages 468-480

  Van Helmond, Zoë ^a   Miners, James S ^a   Kehoe, Patrick G ^a   Love, Seth ^a  

^a FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; APOE; Cerebral amyloid angiopathy; Oligomeric A

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; FORMALDEHYDE; PARAFFIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD VESSEL; BRAIN HOMOGENATE; BRAIN TISSUE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; VASCULAR AMYLOIDOSIS; AGE; BRAIN; COHORT ANALYSIS; GENETICS; METABOLISM; MIDDLE AGED; NEUROFIBRILLARY TANGLE; SENILE PLAQUE; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFIBRILLARY TANGLES; PEPTIDE FRAGMENTS; SENILE PLAQUES; SEX FACTORS; TAU PROTEINS;

EID: 75949101330     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2009.00321.x     Document Type: Article

References (62)

1. Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, Belanger A et al (1992) Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham study. Neurology 42 : 115 119.
2. Bachman DL, Wolf PA, Linn RT, Knoefel JE, Cobb JL, Belanger AJ et al (1993) Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology 43 : 515 519.
3. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M et al (1997) Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 17 : 263 264.
4. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J et al (1999) Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 96 : 15233 15238.
5. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV (2007) Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27 : 909 918.
6. Berg L, McKeel DW Jr., Miller JP, Storandt M, Rubin EH, Morris JC et al (1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55 : 326 335.
7. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82 : 239 259.
8. Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC (2001) Augmented senile plaque load in aged female β-amyloid precursor protein-transgenic mice. Am J Pathol 158 : 1173 1177.
9. Carare RO, Lad M, Horsburgh K, Weller RO (2009) Perivascular drainage of solutes from the brain is modified in the triple transgenic model of Alzheimer's disease: preliminary findings. Neuropathol Appl Neurobiol 35 : 2.
10. Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, Frangione B (1995) Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E. Biochem J 306 : 599 604.
11. Chalmers K, Wilcock GK, Love S (2003) APOE ε4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of Aβ protein. Neuropathol Appl Neurobiol 29 : 231 238.
12. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci 8 : 79 84.
13. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M et al (1988) Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38 : 1682 1687.
14. Dahlgren KN, Manelli AM, Stine WB Jr., Baker LK, Krafft GA, LaDu MJ (2002) Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J Biol Chem 277 : 32046 32053.
15. Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G et al (1988) A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38 : 1688 1693.
16. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB et al (2008) apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J Clin Invest 118 : 4002 4013.
17. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM (2002) Human and murine ApoE markedly alters Aβ metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 9 : 305 318.
18. Fraser T, Tayler H, Love S (2008) Low-temperature improved-throughput method for analysis of brain fatty acids and assessment of their post-mortem stability. J Neurosci Methods 169 : 135 140.
19. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C et al (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373 : 523 527.
20. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE et al (2003) Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100 : 10417 10422.
21. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT (1995) Apolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 38 : 254 259.
22. Greenberg SM, Briggs ME, Hyman BT, Kokoris GJ, Takis C, Kanter DS et al (1996) Apolipoprotein E ε4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 27 : 1333 1337.
23. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM et al (1999) Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19 : 8876 8884.
24. Hemming ML, Selkoe DJ, Farris W (2007) Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis 26 : 273 281.
25. Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K et al (2008) Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res 1216 : 92 103.
26. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ et al (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 97 : 2892 2897.
27. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K et al (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A 96 : 3228 3233.
28. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S et al (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. sci 274 : 99 102.
29. Hy LX, Keller DM (2000) Prevalence of AD among whites: a summary by levels of severity. Neurology 55 : 198 204.
30. Kimura N, Yanagisawa K, Terao K, Ono F, Sakakibara I, Ishii Y et al (2005) Age-related changes of intracellular Aβ in cynomolgus monkey brains. Neuropathol Appl Neurobiol 31 : 170 180.
31. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M et al (2009) Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 106 : 4012 4017.
32. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH et al (1996) Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271 : 4077 4081.
33. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM (2006) Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J Biol Chem 281 : 4292 4299.
34. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A et al (2006) A specific amyloid-β protein assembly in the brain impairs memory. Nature 440 : 352 357.
35. Letenneur L, Commenges D, Dartigues JF, Barberger-Gateau P (1994) Incidence of dementia and Alzheimer's disease in elderly community residents of south-western France. Int J Epidemiol 23 : 1256 1261.
36. Love S, Nicoll JA, Hughes A, Wilcock GK (2003) APOE and cerebral amyloid angiopathy in the elderly. Neuroreport 14 : 1535 1536.
37. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L et al (1999) Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155 : 853 862.
38. Mann DM, Esiri MM (1989) The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 89 : 169 179.
39. Mann DM, Younis N, Stoddart RW, Jones D (1992) The time course of pathological events concerned with plaque formation in Down's syndrome with particular reference to the involvement of microglial cells. Neurodegeneration 1 : 201 215.
40. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K et al (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46 : 860 866.
41. Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG (2006) Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 65 : 1012 1021.
42. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S (2008) Aβ-degrading enzymes in Alzheimer's disease. Brain Pathol 18 : 240 252.
43. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G et al (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39 : 1159 1165.
44. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G et al (2000) High-level neuronal expression of aβ 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20 : 4050 4058.
45. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39 : 409 421.
46. Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R, Thal LJ (1996) The apolipoprotein E ε4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 47 : 190 196.
47. Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye JA, Bird TD et al (1996) Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet 58 : 803 811.
48. Pitschke M, Prior R, Haupt M, Riesner D (1998) Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 4 : 832 834.
49. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN (1996) Apolipoprotein E-ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 148 : 2083 2095.
50. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45 : 358 368.
51. Prohovnik I, Perl DP, Davis KL, Libow L, Lesser G, Haroutunian V (2006) Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology 66 : 49 55.
52. Rocca WA, Bonaiuto S, Lippi A, Luciani P, Turtu F, Cavarzeran F, Amaducci L (1990) Prevalence of clinically diagnosed Alzheimer's disease and other dementing disorders: a door-to-door survey in Appignano, Macerata Province, Italy. Neurology 40 : 626 631.
53. Roelands M, Wostyn P, Dom H, Baro F (1994) The prevalence of dementia in Belgium: a population-based door-to-door survey in a rural community. Neuroepidemiology 13 : 155 161.
54. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I et al (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14 : 837 842.
55. Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A (1993) A population-based study of dementia in 85-year-olds. N Engl J Med 328 : 153 158.
56. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ (2006) Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 572 : 477 492.
57. van Helmond Z, Heesom K, Love S (2009) Characterisation of two antibodies to oligomeric Aβ and their use in ELISAs on human brain tissue homogenates. J Neurosci Methods 176 : 206 212.
58. von Gunten A, Kovari E, Rivara CB, Bouras C, Hof PR, Giannakopoulos P (2005) Stereologic analysis of hippocampal Alzheimer's disease pathology in the oldest-old: evidence for sparing of the entorhinal cortex and CA1 field. Exp Neurol 193 : 198 206.
59. Wang J, Dickson DW, Trojanowski JQ, Lee VM (1999) The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158 : 328 337.
60. Wenham PR, Price WH, Blandell G (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet 337 : 1158 1159.
61. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH et al (2002) The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22 : 1858 1867. (Pubitemid 35386304)
62. Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ (2009) A specific enzyme-linked immunosorbent assay for measuring β-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66 : 190 199.